PanCD44 Immunohistochemical Evaluation in Prostatectomies from Patients with Adenocarcinoma

Table 2

Staining for CD44 in neoplastic cells stratified into negative (0–3) and positive (4–6).

Factor	CD44-negative	CD44-positive	value	OR (95% CI)
PSA
<10	35 (61.4%)	7 (87.5%)	0.242	0.227
≥10	22 (38.6%)	1 (12.5%)		(0.026–1.975)
Gleason score
≤6	31 (54.4%)	6 (75.0%)	0.449	0.397
≥7	26 (45.6%)	2 (25.0%)		(0.074–2.139)
Tumor stage
pT2	42 (73.7%)	7 (87.5%)	0.668	0.400
pT3	15 (26.3%)	1 (2.5%)		(0.045–3.527)
Surgical margins
Free	34 (59.6%)	6 (75.0%)	0.471	0.493
Compromised	23 (40.4%)	2 (25.0%)		(0.091–2.659)
BR
Absent	22 (68.7%)	20 (69.0%)	1.0	0.990
Present	10 (32.3%)	9 (31.0%)		(0.334–2.930)

PSA = prostatic specific antigen; BR = biochemical recurrence; OR (95% CI) = odds ratio and 95% confidence interval; percentage. The level of significance was evaluated with Fisher’s exact test.